Stem Cell Biotechnology in Ocular Regenerative Medicine and Drug Discovery
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Methods".
Deadline for manuscript submissions: closed (5 July 2023) | Viewed by 32353
Special Issue Editors
Interests: novel human stem cell-based tools for the retinal and corneal regeneration through cell transplantation and ophthalmic in vitro cell and 3D tissue models for disease modeling and therapy development
Special Issue Information
Dear Colleagues,
The eyes are sensory organs endowed with unique features in terms of both structure and function. It is easily accessible and visualized, which is useful both for in vivo diagnostics and topical therapy. It consists of various types of cellular lineages that are embryologically of ectodermal, mesodermal, and endodermal origins. Dysfunction of these different elements, which are crucial to the eye’s structure and function, commonly results in vision-related problems and can even cause blindness. However, these unique features of the eye make it ideally suited for supporting various emerging techniques such as cell therapy, tissue engineering, and gene therapy.
We are pleased to invite all basic and clinic researchers to contribute to our Special Issue on ‘Stem Cell Biotechnology in Ocular Regenerative Medicine and Drug Discovery’. In this Special Issue, we propose presenting the most recent updates on research in regenerative ophthalmology and drug discovery, which are at the cusp of clinical translation, starting from the front to the back of the eye. Different cell therapies involving, e.g., limbal, corneal, endothelial and stromal, and conjunctival stem cells have emerged for ocular surface restoration and corneal endothelial disorders. Lacrimal gland regeneration and trabecular meshwork stem cells are evolving technologies for treating dry eye disease and glaucoma, respectively. The retinal tissue of neural origin raised the need to explore newer modalities of therapy such as cells derived from pluripotent stem cells and gene therapy for inherited retinal disorders. The use of biosynthetic corneas, artificial corneal implants, and the development of the bionic eye with artificial intelligence has offered enticing avenues for eyes afflicted with blinding diseases. This Special Issue will summarize the most exciting new therapeutic approaches that could revolutionize the treatment of vision impairment and blindness through disruptive and innovative scientific breakthroughs.
In this Special Issue, both original research articles and reviews are welcome. Research areas may include but are not limited to stem cell-based therapies, novel drug therapies, ocular organoids and gene editing, and related therapeutics. We look forward to receiving your contributions.
Prof. Dr. Heli Skottman
Prof. Dr. Sayan Basu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ocular regenerative therapy
- stem cells, pluripotent stem cells
- retinal pigment epithelium
- neural retina
- cornea
- limbal epithelial stem cells
- stem cell transplant
- gene therapy
- drug discovery
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.